Related Experiment Video
Updated: Jun 22, 2026
11:49
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
Genous endothelial progenitor cell-capturing stent system: a novel stent technology
Margo Klomp1, Marcel A M Beijk, Robbert J de Winter
1Academic Medical Center, University of Amsterdam, Department of Cardiology, B2-137, Meibergdreef 9, PO Box 22660, 1105 AZ, Amsterdam, The Netherlands.
Expert Review of Medical Devices
|July 4, 2009
Summary
A novel endothelial progenitor cell-capturing stent promotes healing by accelerating re-endothelialization, potentially reducing in-stent restenosis. Ongoing studies compare its effectiveness against traditional bare-metal and drug-eluting stents.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
- Regenerative Medicine
Background:
- Drug-eluting stents (DES) reduce restenosis but use cytotoxic agents.
- A prohealing approach promoting endothelialization is a desirable alternative.
- Endothelial progenitor cell (EPC)-capturing stents offer a novel strategy.
Purpose of the Study:
- To review the development and clinical performance of EPC-capturing stents.
- To compare EPC-capturing stents with bare-metal stents (BMS) and DES.
- To discuss future perspectives for this prohealing stent technology.
Main Methods:
- Review of existing literature and clinical data on EPC-capturing stents.
- Discussion of the mechanism of action: attraction and differentiation of circulating progenitor cells.
- Reference to the Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth (HEALING) studies and CE mark approval.
- Mention of the ongoing Tri-stent Adjudication Study (TRIAS) for direct comparison.
Main Results:
- EPC-capturing stents attract circulating progenitor cells to form a functional endothelial layer.
- This accelerated endothelialization is theorized to reduce neointimal hyperplasia and smooth muscle cell proliferation.
- Initial safety and efficacy demonstrated in nonrandomized HEALING studies.
- CE mark obtained in 2005.
Conclusions:
- EPC-capturing stents represent a promising prohealing alternative to DES.
- Further evidence from randomized trials like TRIAS is crucial to establish clinical superiority.
- This technology has the potential to improve outcomes in coronary artery disease treatment.
